Throughout its history, CELLONTECH has focused its R&D efforts on regenerative therapies, aesthetic treatments, blood and immune disorder treatments, in areas such as bone joints, cartilage, bones, connective tissues (ligaments-tendons), and skin. By leveraging the essential factors of 'cells' and 'biomaterials' that constitute human tissues, CELLONTECH has successfully commercialized a wide range of advanced regenerative medical products centered around independently developed BioCollagen materials.
Moving forward, CELLONTECH will continue to concentrate on research and development to commercialize bio-material products that can be utilized in various organ regeneration and reconstruction, aiming to grow as a leading global bio-healthcare company.
Company Name | CELLONTECH Co., Ltd. |
---|---|
Establishment Date | Original Establishment Date : April 2, 2000 ㅣ Split Establishment : April 2, 2021 |
CEO | Hyung Jin Woo |
Business Areas |
|
Domestic Business Locations |
|
-
Certificate of Recognition
for Corporate-affiliated Research Institute -
Venture Company Certification